FR3058143B1 - Nanocorps anti-tau - Google Patents

Nanocorps anti-tau Download PDF

Info

Publication number
FR3058143B1
FR3058143B1 FR1660450A FR1660450A FR3058143B1 FR 3058143 B1 FR3058143 B1 FR 3058143B1 FR 1660450 A FR1660450 A FR 1660450A FR 1660450 A FR1660450 A FR 1660450A FR 3058143 B1 FR3058143 B1 FR 3058143B1
Authority
FR
France
Prior art keywords
tau
nanocbodies
relates
present
nanobodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1660450A
Other languages
English (en)
Other versions
FR3058143A1 (fr
Inventor
Daniel Fagret
Marcelle Moulin
Catherine Ghezzi
Pascale Perret
Sabine Chierici
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Universitaire de Grenoble
Universite Grenoble Alpes
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Universitaire de Grenoble
Universite Grenoble Alpes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1660450A priority Critical patent/FR3058143B1/fr
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Centre Hospitalier Universitaire de Grenoble, Universite Grenoble Alpes filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to CA3041066A priority patent/CA3041066A1/fr
Priority to CN201780080870.6A priority patent/CN110225926B/zh
Priority to JP2019545850A priority patent/JP7197494B2/ja
Priority to US16/345,279 priority patent/US10590191B2/en
Priority to PCT/EP2017/077691 priority patent/WO2018078140A1/fr
Priority to EP17798139.6A priority patent/EP3532495A1/fr
Publication of FR3058143A1 publication Critical patent/FR3058143A1/fr
Application granted granted Critical
Publication of FR3058143B1 publication Critical patent/FR3058143B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La présente invention concerne des nanocorps anti-Tau.
FR1660450A 2016-10-27 2016-10-27 Nanocorps anti-tau Active FR3058143B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR1660450A FR3058143B1 (fr) 2016-10-27 2016-10-27 Nanocorps anti-tau
CN201780080870.6A CN110225926B (zh) 2016-10-27 2017-10-27 抗Tau纳米抗体
JP2019545850A JP7197494B2 (ja) 2016-10-27 2017-10-27 抗Ｔａｕナノボディ
US16/345,279 US10590191B2 (en) 2016-10-27 2017-10-27 Anti-tau nanobodies
CA3041066A CA3041066A1 (fr) 2016-10-27 2017-10-27 Nanocorps anti-tau
PCT/EP2017/077691 WO2018078140A1 (fr) 2016-10-27 2017-10-27 Nanocorps anti-tau
EP17798139.6A EP3532495A1 (fr) 2016-10-27 2017-10-27 Nanocorps anti-tau

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1660450 2016-10-27
FR1660450A FR3058143B1 (fr) 2016-10-27 2016-10-27 Nanocorps anti-tau

Publications (2)

Publication Number Publication Date
FR3058143A1 FR3058143A1 (fr) 2018-05-04
FR3058143B1 true FR3058143B1 (fr) 2021-03-12

Family

ID=58314353

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1660450A Active FR3058143B1 (fr) 2016-10-27 2016-10-27 Nanocorps anti-tau

Country Status (6)

Country Link
US (1) US10590191B2 (fr)
EP (1) EP3532495A1 (fr)
JP (1) JP7197494B2 (fr)
CA (1) CA3041066A1 (fr)
FR (1) FR3058143B1 (fr)
WO (1) WO2018078140A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA47499A (fr) 2017-02-17 2019-12-25 Denali Therapeutics Inc Anticorps anti-tau et leurs procédés d'utilisation
CN112649615A (zh) * 2020-12-21 2021-04-13 大连理工大学 一种检测不同大小的可溶性Aβ寡聚体的方法及应用
FR3134390A1 (fr) 2022-04-11 2023-10-13 Universite Grenoble Alpes Peptide utile pour le transport de molecules au travers de barrieres cellulaires

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
DE69434860T2 (de) 1993-02-22 2007-03-15 The Rockefeller University Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
MX9701720A (es) 1994-09-12 1997-06-28 Schering Ag Proceso para la fabricacion de una palidipina modificada, inhibidora de la agregacion plaquetaria inducida por colageno.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
EP2470211B1 (fr) * 2009-08-28 2016-01-27 The Board of Regents of The University of Texas System Anticorps liant les oligomères de la protéine tau
GB201112056D0 (en) * 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
CN104185640B (zh) * 2011-09-19 2018-07-20 阿克松神经系统科学公司 阿尔茨海默病中的tau蛋白介导病变的基于蛋白质的疗法和诊断
EP4356927A2 (fr) * 2012-10-12 2024-04-24 Arizona Board of Regents on behalf of Arizona State University Réactifs à base d'anticorps qui reconnaissent spécifiquement des formes oligomériques toxiques de tau
EP2899208A1 (fr) * 2014-01-28 2015-07-29 F.Hoffmann-La Roche Ag Anticorps à domaine unique de camélidés dirigés contre des protéines tau phosphorylées et procédés de production de conjugués de ceux-ci

Also Published As

Publication number Publication date
FR3058143A1 (fr) 2018-05-04
CA3041066A1 (fr) 2018-05-03
US20190263898A1 (en) 2019-08-29
EP3532495A1 (fr) 2019-09-04
WO2018078140A1 (fr) 2018-05-03
US10590191B2 (en) 2020-03-17
JP2020505056A (ja) 2020-02-20
CN110225926A (zh) 2019-09-10
JP7197494B2 (ja) 2022-12-27

Similar Documents

Publication Publication Date Title
CY1122398T1 (el) Συνδυαστικες θεραπειες με αντισωματα anti-cd38
EA202092435A3 (ru) Моноклональные антитела против bcma
CL2017001393S1 (es) Automovil
BR112018014135A2 (pt) dispensador com um suporte de cartucho
PH12016501763A1 (en) Multispecific antibodies
TR201905829T4 (tr) Buzdolabı.
BR112018006471A2 (pt) compostos úteis como moduladores de trpm8
EA201992177A1 (ru) Композиции на основе нирапариба
CL2017001185S1 (es) Automovil
TR201909606T4 (tr) Pi̇razollari hazirlamak i̇çi̇n i̇şlem
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
TR201910057T4 (tr) Kauçuk bi̇leşi̇mleri̇
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
TR201908795T4 (tr) Bi̇r şeki̇llendi̇ri̇lebi̇li̇r kütleni̇n şeki̇llendi̇ri̇lmesi̇ i̇çi̇n ci̇haz
FR3058143B1 (fr) Nanocorps anti-tau
TR201904143T4 (tr) Silillenmiş poliüretanlar.
FR3044927B1 (fr) Emulsion magnetique reactive
UA114708U (uk) Тяговий привід електробуса
MA44833A (fr) Nanoparticules extrêmement petites de polymères dégradables
TR201401768A2 (tr) Miyasteninin tedavisine yönelik bir kompozisyon.
ECSDI15050234S (es) Motocicleta
TR201401766A2 (tr) Asteninin tedavisine yönelik bir kompozisyon.
MX2016016577A (es) Aleacion de fundicion de aluminio.
GT201400051S (es) Escúter o motoneta

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20180504

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

TQ Partial transmission of property

Owner name: UNIVERSITE GRENOBLE ALPES, FR

Effective date: 20220620

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERC, FR

Effective date: 20220620

Owner name: CENTRE HOSPITALIER UNIVERSITAIRE GRENOBLE, FR

Effective date: 20220620

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8